港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

高瓴概念

470.710

-8.991-1.87%

涨家数：23

跌家数：29

平家数：3

市盈率：- -

高：482.424

开：479.701

低：469.662

收：479.701

数据加载中...

总览新闻资讯

医疗器械行业开局再度遇冷 IVD板块成为业绩“重灾区” | 2024器械行业年报

新天绿色能源(00956)4月按合并报表口径完成发电量147.78万兆瓦时同比增加16.91%

石药集团(01093)：SYH2046片获美国临床试验批准

即时零售大战前传：互联网健康的十年“三国杀”

华尔街见闻

恒瑞医药(600276.SH)：SHR-1316(sc)注射液获得药物临床试验批准通知书

翰森制药(03692)：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书

翰森制药：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书

翰森制药(03692.HK)阿美乐第四项适应症获发药品注册证书

阿斯达克财经

归创通桥(02190)5月9日斥资95.85万港元回购5万股

东方雨虹：因金科股份存在欠款已接受其持有的部分金科服务股份质押

“太平洋医药”君实生物公司点评：拓益收入同比增长 46%，关注 DKK1 胃肠道肿瘤早期数据

时代天使新品上市有望进一步夯实竞争优势，长期发展动能强劲

“科企专线”来了！创新药企或受益

中国商报网

高视医疗附属公司新型人工晶状体植入系统获批医疗器械注册证

重庆市涪陵区市场监管局开展医疗器械网售环节专项检查

中国质量新闻网

复星医药子公司获美国FDA批准开展AGA治疗临床试验

高视医疗(02407)：人工晶状体植入系统获得中国医疗器械注册证

高视医疗(02407.HK)人工晶状体植入系统获中国医疗器械注册证

阿斯达克财经

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1583/news?page=11"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":470.7096,"timestamp":1747123711788,"preClose":479.70102,"halted":0,"volume":457379627,"delay":0,"changeRate":-0.018744,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-8.991425,"latestTime":"05-13 16:00:00","open":479.70102,"high":482.42447,"low":469.6616,"amount":14516179954,"amplitude":0.026606,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1747186200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1747099800000,1747108800000],[1747112400000,1747123200000]],"pbRate":2.269203,"peRate":21.770339,"turnoverRate":0.003175,"increases":23,"decrements":30,"flats":1,"marketCap":2664799825984,"floatMarketCap":2087029888320},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":482.42447,"amplitude":0.026606,"preClose":479.70102,"low":469.6616,"pbRate":"2.269203","latestPrice":470.7096,"volume":457379627,"delay":0,"open":479.70102,"prevYearClose":446.93042,"prevWeekClose":480.539,"prevMonthClose":473.358,"prevQuarterClose":505.776,"fiveDayClose":485.703,"twentyDayClose":463.61,"sixtyDayClose":470.714,"secType":"PLATE","market":"HK","turnoverRate":0.003175,"peRate":21.770339,"marketCap":2664799825984,"floatMarketCap":2087029888320,"timestamp":1747123711788,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":23,"down":29,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:11,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2534101351","title":"医疗器械行业开局再度遇冷 IVD板块成为业绩“重灾区” | 2024器械行业年报","url":"https://stock-news.laohu8.com/highlight/detail?id=2534101351","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534101351?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:39","pubTimestamp":1746787140,"startTime":"0","endTime":"0","summary":"　　2024年，中国医疗器械行业在政策调整、市场需求波动与全球供应链重构的多重挑战中艰难企稳，全年收入增速转正至0.78%，但利润端分化显著。进入2025年，行业开局再度遇冷，Q1营收、归母净利润、扣非净利润同比下滑6.87%、12.17%、17.42%。医疗设备招标滞后、IVD集采冲击及高值耗材需求波动成为主因。　　医疗设备板块呈现深度调整态势，全板块营业收入同比下滑4.1%，归母净利润与扣非归母净利润分别大幅收缩35.5%和38.8%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2025-05-09/doc-inevyhfv9172518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1222","159883","BK1100","09996","09997","BK1583","BK1574"],"gpt_icon":0},{"id":"2534610679","title":"新天绿色能源(00956)4月按合并报表口径完成发电量147.78万兆瓦时 同比增加16.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534610679","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534610679?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:37","pubTimestamp":1746787026,"startTime":"0","endTime":"0","summary":"智通财经APP讯，新天绿色能源 发布公告，2025年4月，该集团按合并报表口径完成发电量147.78万兆瓦时，同比增加16.91%。截至2025年4月30日，累计完成发电量602.20万兆瓦时，同比增加11.91%。截至2025年4月30日，累计完成输╱售气量219714.10万立方米，同比减少17.09%，其中售气量201505.79万立方米，同比减少14.85%;代输气量18208.30万立方米，同比减少35.78%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1558","BK1503","BK1594","BK1166","BK1583","00956"],"gpt_icon":0},{"id":"2534106973","title":"石药集团(01093)：SYH2046片获美国临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106973","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106973?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:31","pubTimestamp":1746786691,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的化药1类新药SYH2046片(该产品)已获得美国食品药品监督管理局批准，可以在美国开展临床试验。该产品是一款具有完全自主知识产权的全新结构first-in-class小分子药物，本次获批的临床试验适应症为急性心肌梗死后心力衰竭。临床前研究表明，该产品可显着改善疾病动物模型的心脏功能并降低心脏不良重构，且具有较高的安全性。目前，本集团已在国内外提交该产品的多项专利申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291470.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0326950275.SGD","03347","IE00BZ08YT58.USD","LU1152091168.USD","LU1951186391.HKD","LU1226288170.HKD","LU0140636845.USD","BK1521","IE0008368742.USD","LU1152091754.HKD","LU0067412154.USD","01093","BK1576","BK1515","IE00B031HY20.USD","LU0880133367.SGD","LU1226287875.USD","IE00B5MMRT66.SGD","LU1960683339.HKD","LU1807302812.USD","LU1008478684.HKD","IE00BZ08YR35.GBP","LU1226287529.USD","BK1191","SG9999004220.SGD","IE00B543WZ88.USD","BK1141","IE0008369823.USD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226287792.SGD","LU1993786604.SGD","BK1583","LU0501845795.SGD","LU1226288253.USD"],"gpt_icon":0},{"id":"2534106420","title":"即时零售大战前传：互联网健康的十年“三国杀”","url":"https://stock-news.laohu8.com/highlight/detail?id=2534106420","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534106420?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 18:24","pubTimestamp":1746786254,"startTime":"0","endTime":"0","summary":"互要流量","market":"us","thumbnail":"https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png","type":0,"news_type":0,"thumbnails":["https://wpimg-wscn.awtmt.com/80a4ddb7-699e-49c8-b5bb-3d8b9af64cea.png"],"rights":{"source":"wallstreetcn_hot_news","url":"https://wallstreetcn.com/articles/3746786","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3746786","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"wallstreetcn_hot_news","symbols":["LU0181495838.USD","LU1328277881.USD","ALBmain","LU1046422090.SGD","LU0890818403.SGD","BK1583","LU1720051108.HKD","LU2125910500.SGD","LU0315179316.USD","LU0651946864.USD","00241","LU0871576103.HKD","LU0531971595.HKD","09939","LU2257852520.SGD","LU0128525689.USD","LU1282651121.HKD","LU1201861165.SGD","06618","BK1515","LU0594300179.USD","BK4524","LU1044876610.USD","LU1808992512.USD","03690","89988","BK1584","HBBD.SI","LU0700851271.USD","BK4579","LU0348827113.USD","LU1675838814.USD","LU0140636845.USD","LU0359201885.HKD","86618","MPNGY","LU2242644610.SGD","METmain","89618","LU0819123356.HKD","LU0231483743.USD","LU2097828474.EUR","LU0463099449.HKD","BK4504","HMTD.SI","LU0029875118.USD"],"gpt_icon":1},{"id":"2534177637","title":"恒瑞医药(600276.SH)：SHR-1316(sc)注射液获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177637","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177637?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:55","pubTimestamp":1746784534,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1316(sc)注射液的《药物临床试验批准通知书》，将于近期开展临床试验。具体为SHR-1316(sc)联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌中的药代动力学、安全性、耐受性及疗效的开放、多中心Ⅰ期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0183","LU0405327494.USD","BK1583","03347","LU2488822045.USD","BK0196","BK0188","BK0012","BK1576","LU0405327148.USD","LU1328615791.USD","BK0028","LU2328871848.SGD","LU1969619763.USD","BK0060","BK0239","600276","LU1064131003.USD","LU1064130708.USD","BK1141","LU2148510915.USD"],"gpt_icon":0},{"id":"2534177653","title":"翰森制药(03692)：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534177653","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534177653?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:55","pubTimestamp":1746784500,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药(03692)发布公告，本集团创新药阿美乐®(甲磺酸阿美替尼片)获中国国家药品监督管理局(NMPA)签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体(“EGFR”)外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌“NSCLC”)患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐®获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03692","BK1589","BK1191","BK1583"],"gpt_icon":0},{"id":"2534999483","title":"翰森制药：阿美乐®(甲磺酸阿美替尼片)第四项适应症获国家药品监督管理局签发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534999483","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534999483?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:53","pubTimestamp":1746784413,"startTime":"0","endTime":"0","summary":"格隆汇5月9日丨翰森制药发布公告，集团创新药阿美乐获中国国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21置换突变的成人非小细胞肺癌“NSCLC”）患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917533394f19c65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","03692","BK1583","BK1589"],"gpt_icon":0},{"id":"2534558177","title":"翰森制药(03692.HK)阿美乐第四项适应症获发药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2534558177","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534558177?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:50","pubTimestamp":1746784200,"startTime":"0","endTime":"0","summary":"翰森制药(03692.HK) 公布，创新药阿美乐获国家药品监督管理局签发的药品注册证书，批准增加“用于II-IIIB期具有表皮生长因子受体外显子19缺失或外显子21(L858R)置换突变的成人非小细胞肺癌患者的治疗，患者须既往接受过手术切除治疗，并由医生决定接受或不接受辅助化疗”适应症。此为阿美乐获批的第四项适应症。阿美乐是中国首个原研三代EGFR-TKI创新药，此前已于中国获批三项适应症。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-09 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201021164015908_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1438988/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1583","03692","BK1191","BK1589"],"gpt_icon":0},{"id":"2534171299","title":"归创通桥(02190)5月9日斥资95.85万港元回购5万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2534171299","media":"智通财经","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534171299?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:37","pubTimestamp":1746783453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)发布公告，于2025年5月9日斥资95.85万港元回购股份5万股，每股回购价格为18.86-19.82港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1587","BK1100","02190","BK1574"],"gpt_icon":0},{"id":"2534849177","title":"东方雨虹：因金科股份存在欠款已接受其持有的部分金科服务股份质押","url":"https://stock-news.laohu8.com/highlight/detail?id=2534849177","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534849177?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:31","pubTimestamp":1746783076,"startTime":"0","endTime":"0","summary":"证券之星消息，东方雨虹05月09日在投资者关系平台上答复投资者关心的问题。已经超过24年净利润200%了东方雨虹董秘：您好，因金科股份对公司存在欠款，公司作为其债权人，已接受金科股份将其持有的部分金科服务股份质押给我司。目前该部分质押股份尚未过户至我公司名下，公司尚未对其进行处置。公司未来如有相关计划，将严格按照深圳证券交易所的规定及时履行信息披露义务。感谢您对东方雨虹的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173642a6d8e2dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173642a6d8e2dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1542","09666","BK1258","BK1583","BK1229"],"gpt_icon":0},{"id":"2534991171","title":"“太平洋医药”君实生物公司点评：拓益收入同比增长 46%，关注 DKK1 胃肠道肿瘤早期数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2534991171","media":"新浪财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534991171?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:22","pubTimestamp":1746782527,"startTime":"0","endTime":"0","summary":"拓益销售收入保持高增速，公司运营效率显著提升，在手现金 30 亿元。2025 年第一季度公司实现收入 5 亿元， 其中，核心产品特瑞普利单抗于国内市场实现销售收入 4.47 亿元。研发费用 3.51 亿元，同比增加 26.89%；管理费用 0.97 亿元，同比减少 21.32%。拓益国内获批 12 项适应症，国际化布局进展顺利。截止目前，拓益已于国内获批 12 项适应症，10 项适应症纳入国家医保目录，其中 4 项为医保独家适应症。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917245897544f69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917245897544f69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01877","09939","BK1161","BK1515","BK1583","BK1574"],"gpt_icon":0},{"id":"2534483943","title":"时代天使新品上市有望进一步夯实竞争优势，长期发展动能强劲","url":"https://stock-news.laohu8.com/highlight/detail?id=2534483943","media":"国金证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534483943?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 17:16","pubTimestamp":1746782176,"startTime":"0","endTime":"0","summary":"截至2024年底，时代天使在中国市场完成了21.87万例隐形矫治案例，同比增长3.2%，但收入同比略有下降。预计随着防龋齿矫治器的全面上市，公司将巩固其市场地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173146a477f2cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509173146a477f2cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1587","BK1583","BK1593","06699"],"gpt_icon":0},{"id":"2534071480","title":"“科企专线”来了！创新药企或受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2534071480","media":"中国商报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534071480?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 16:58","pubTimestamp":1746781107,"startTime":"0","endTime":"0","summary":"业内人士认为，“科企专线”是继“18A规则”后资本市场对生物科技公司释放的又一个利好信号。因此，上市对创新药企来说至关重要。未盈利的创新药企有望受益此前，“生物科技公司”在港交所申请上市遵循香港《上市规则》中的第18A章，业内称“18A规则”。有数据显示，截至5月7日，经“18A规则”在港股上市的创新药械企业已经累计达到65家。头部港股创新药公司受益于出海成果放量，营收和利润稳步增长。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917262094f195fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050917262094f195fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2488822045.USD","02359","02269","BK1583","BK1574","LU2328871848.SGD","01801","06978","BK1161","LU1969619763.USD","09926","BK1589"],"gpt_icon":0},{"id":"2534517553","title":"高视医疗附属公司新型人工晶状体植入系统获批医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2534517553","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534517553?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 16:51","pubTimestamp":1746780712,"startTime":"0","endTime":"0","summary":"5月9日，高视医疗（02407）发布公告，近日公司全资附属公司高视泰靓医疗科技有限公司的“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。该注册证编号为粤械注准20252160605，主要适用于微小切口白内障手术中的人工晶状体植入手术。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505093400638738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09996","BK1100","BK1222","BK1583","09997","02407","BK1574"],"gpt_icon":0},{"id":"2534088176","title":"重庆市涪陵区市场监管局开展医疗器械网售环节专项检查","url":"https://stock-news.laohu8.com/highlight/detail?id=2534088176","media":"中国质量新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534088176?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 16:39","pubTimestamp":1746779940,"startTime":"0","endTime":"0","summary":"5月9日，执法人员在一家医疗器械销售单位通过检查下单记录检查医疗器械网售情况。中国质量新闻网讯 连日来，重庆市涪陵区市场监管局持续开展了医疗器械网售环节专项检查。此次行动，执法人员通过对各医疗器械销售单位医疗器械网上下单情况及销售记录、医疗器械追溯体系落实情况进行拉网式检查，防止来路不明、质量不合格医疗器械网售行为侵犯消费者的合法权益。（朱小娅 文光辉）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-09/doc-inevyhfs7446655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","09996","BK1100","BK1583","BK1222","09997","159883"],"gpt_icon":0},{"id":"2534173533","title":"复星医药子公司获美国FDA批准开展AGA治疗临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2534173533","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534173533?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 16:37","pubTimestamp":1746779855,"startTime":"0","endTime":"0","summary":"5月9日，复星医药发布公告，控股子公司菌济健康获得美国FDA关于LBP-ShC4开展临床试验的批准。公告指出，目前全球尚无用于治疗雄激素脱发的活体生物治疗产品获批上市。尽管获得临床试验批准，但药品研发存在风险，后续的临床研究仍需获得美国药品审评部门的审批，且临床试验可能因安全性和有效性问题而终止。2025年一季度，复星医药实现收入94.20亿元，归母净利润7.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250509164519a477e291&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1583","BK1515","BK1141","BK1191","BK1593","02196","03347"],"gpt_icon":0},{"id":"2534178159","title":"高视医疗(02407)：人工晶状体植入系统获得中国医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2534178159","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534178159?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 16:37","pubTimestamp":1746779821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，高视医疗 发布公告，近日本公司全资附属公司高视泰靓医疗科技有限公司之“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。高视泰靓本次获批的人工晶状体植入系统，主要适用于微小切口白内障手术中的人工晶状体植入手术。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1291333.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1222","BK1100","09996","02407","159883","BK1583","BK1574","09997"],"gpt_icon":0},{"id":"2534173843","title":"高视医疗(02407.HK)人工晶状体植入系统获中国医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2534173843","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534173843?lang=zh_cn&edition=fundamental","pubTime":"2025-05-09 16:36","pubTimestamp":1746779760,"startTime":"0","endTime":"0","summary":"高视医疗(02407.HK) 公布，近日公司全资附属高视泰靓之“人工晶状体植入系统”已获得由广东省药品监督管理局批准的医疗器械注册证。高视泰靓本次获批的人工晶状体植入系统，主要适用于微小切口白内障手术中的人工晶状体植入手术。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20221221155533842_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20221221155533842_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1438958/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1222","09996","159883","02407","09997","BK1574","BK1100","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":36,"pageCount":11,"totalSize":715,"code":"91000000","status":"200"}]}}